3 recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Recruiting 3 |
Follow I-Dxd: new trials by email Literature Review of I-Dxd trials Research Report on I-Dxd
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) Ifinatamab deruxtecan, Docetaxel, Prednisone - Prostate Cancer, Prostatic Neoplasms | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1440 | 2025-05-13 | 2026-10-30 |
| A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) Ifinatamab deruxtecan, Docetaxel, Paclitaxel - Esophageal Squamous Cell Carcinoma | Phase 3 | Recruiting | Daiichi Sankyo | 510 | 2025-03-27 | 2026-10-26 |
| A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer Ifinatamab deruxtecan, Topotecan, Amrubicin - Small Cell Lung Cancer | Phase 3 | Recruiting | Daiichi Sankyo | 540 | 2024-05-21 | 2026-08-06 |
Esophageal Squamous Cell Carcinoma (1) · Prostatic Neoplasms (1) · Small Cell Lung Carcinoma (1)
Daiichi Sankyo (2) · Merck Sharp & Dohme LLC (1)
China (3) · France (3) · Germany (3) · Italy (3) · Japan (3) · Netherlands (3) · Poland (3) · South Korea (3) · Spain (3) · Taiwan (3) · United States (3) · Australia (2) · Austria (2) · Belgium (2) · Brazil (2)
2023 (2)